We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Global Urinalysis Test Market Driven by Increasing Prevalence of Chronic Kidney Disease and Diabetes

By LabMedica International staff writers
Posted on 14 Apr 2023
Print article
Image: The global urinalysis test market is expected to surpass USD 6 billion by 2031 (Photo courtesy of Freepik)
Image: The global urinalysis test market is expected to surpass USD 6 billion by 2031 (Photo courtesy of Freepik)

The global urinalysis test market is growing due to factors such as the rising prevalence of chronic diseases like chronic kidney disease and diabetes, an increase in the geriatric population, and heightened awareness about the importance of regular health checkups. However, market growth is hindered by a shortage of skilled laboratory technicians. Nonetheless, the development of advanced urine analyzers is expected to create new growth opportunities in the near future. As a result, the global urinalysis test market, valued at USD 3.19 billion in 2021, is projected to experience a CAGR of 6.7% from 2022 to 2031, reaching USD 6.12 billion by 2031. These are the latest findings of Allied Market Research (Portland, OR, USA), a market research firm.

The COVID-19 pandemic adversely impacted the global urinalysis test market, as demand for urinalysis devices and consumables decreased due to lower hospitalization rates. Furthermore, sales of urinalysis tests declined during the early stages of the pandemic, and reduced hospital visits for urinalysis tests led to a decline in the adoption of urinalysis devices, thereby hampering market growth. However, the market has gradually recovered and is expected to grow steadily, primarily driven by the increasing incidence of urological disorders.

In 2021, the consumables segment held the largest share of the global urinalysis test market, accounting for over three-fourths of total revenue, and is expected to maintain its dominance throughout the forecast period. This segment is also projected to register the fastest CAGR of 6.9% during this time, owing to technological advancements in urinalysis consumables and high adoption of reagents and strips.

The disease screening segment held the largest share of the global urinalysis test market in 2021, accounting for over half of total revenue, and is expected to remain dominant throughout the forecast period. This segment is also expected to register the fastest CAGR of 7% during this time, mainly due to increased adoption of urinalysis devices for disease screening.

In 2021, the diagnostic laboratories segment accounted for the largest share of the global urinalysis test market, contributing around two-fifths of total revenue, and is expected to maintain its dominance throughout the forecast period. This segment is also expected to register the fastest CAGR of 7% during this time, primarily due to an increase in the prevalence of chronic diseases such as diabetes and kidney disease, which has led to a surge in demand for urinalysis tests among diagnostic laboratories.

Regionally, North America held the largest share of the global urinalysis test market in 2021, accounting for over two-fifths of total revenue, and is likely to continue dominating the market during the forecast period. Factors such as easy availability of diagnostic products, well-developed healthcare infrastructure, increased awareness about early disease diagnosis, and higher adoption of advanced diagnostic tools drive the growth of the North American urinalysis test market. However, the Asia-Pacific urinalysis test market is expected to register the fastest CAGR of 7.4% during the forecast period, driven by increased health awareness, development in healthcare infrastructure, and a surge in awareness of preventive healthcare in the region.

Related Links:
Allied Market Research

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: The device can serve as a sample pretreatment tool for cytological diagnosis of malignant effusions (Photo courtesy of Microsystems & Nanoengineering: Zhu, Z., Ren, H., Wu, D. et al.)

Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities

Tumor cell clusters are increasingly recognized as crucial in cancer pathophysiology, with growing evidence of their increased resistance to treatment and higher metastatic potential compared to single tumor cells.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.